{"prompt": "['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', '5.5.2', 'Identity of Investigational Product(s)', 'Table 3.', 'Identity of Investigational Products', 'Placebo for', 'Investigational', 'Rovalpituzumab', 'Rovalpituzumab', 'Placebo for', 'Product', 'Tesirine', 'Tesirine', 'Dexamethasone*', 'Dexamethasone', 'Dosage Form', 'Powder for', 'Powder for', 'Capsules', 'Placebo capsules', 'solution for', 'solution for', 'infusion in vials', 'infusion in vials', 'Strength', '10 mg/ml when', 'N/A', '8 mg', 'N/A', 'reconstituted with', '3.2 ml of sterile', 'water for injection', 'Route of', 'Intravenous', 'Intravenous', 'Oral', 'Oral', 'Administration', '*', 'Commercially-available Dexamethasone tablets are over-encapsulated to maintain study blinding.', 'AbbVie will supply rovalpituzumab tesirine/placebo and dexamethasone/placebo.', 'Each site will be responsible for maintaining drug accountability records, including', 'product description, manufacturer, and lot numbers for all investigational products', 'dispensed by the site.', '5.5.2.1', 'Packaging and Labeling', 'Rovalpituzumab Tesirine and Placebo', 'Vials of rovalpituzumab tesirine/placebo will be packaged in cartons. Each vial and', 'carton will be labeled per country requirements. Labels must remain affixed to the vial', 'and carton. Rova-T drug product is classified as a Dangerous Goods/Hazardous Material', 'and is packaged and shipped by AbbVie according to US Department of Transportation', '(DOT) and International Air Transport Association (IATA) certified regulations.', '65']['abbvie Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'Dexamethasone and Placebo', 'Dexamethasone/placebo will be packaged in high-density polyethylene (HDPE) bottles', 'according to the study needs. The bottles will be labeled per country requirements.', 'Labels must remain affixed to the containers.', '5.5.2.2', 'Storage and Disposition of Blinded Investigational', 'Product(s)', 'For all storage areas and refrigerators, temperature logs will be maintained to document', 'proper storage conditions. The temperature must be recorded on the temperature logs to', 'verify proper function on each business day. Temperature excursions must be reported to', 'AbbVie immediately.', 'Sites should use the AbbVie Temperature Excursion Management System (ATEMS)', 'module via IRT, if available, or fax copies of the temperature log indicating the extent of', 'the excursion (time, duration of the temperature excursion, min/max values and study', 'drugs affected) to AbbVie Clinical Drug Supply Management (CDSM) including the', 'Storage Temperature Excursion Reporting Form.', 'In case of a temperature excursion, study medication should be quarantined and not', 'dispensed until AbbVie CDSM or ATEMS deems the medication as acceptable.', 'The investigational products are for investigational use only and are to be used only', 'within the context of this study. The study drug supplied for this study must be', 'maintained under adequate security and stored under the conditions specified on the label', 'until dispensed for subject use or returned to the destruction facility.', 'Rovalpituzumab Tesirine/Placebo', 'Rovalpituzumab tesirine/placebo must be stored refrigerated at 2\u00b0 to 8\u00b0C (36\u00b0 to 46\u00b0F),', 'protected from light, and must not be frozen. Specific storage conditions for reconstituted', 'and diluted rovalpituzumab tesirine/placebo will be provided in a separate document', 'outside of this protocol.', '66']['abbvie Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'Dexamethasone/Placebo', 'Dexamethasone/placebo should be stored at 15\u00b0 to 25\u00b0C (59\u00b0 to 77\u00b0F) and protected from', 'light. For Australia, dexamethasone/placebo should be stored below 25\u00b0C and protected', 'from light.', '5.5.2.3', 'Preparation/Reconstitution of Dosage Form(s)', 'Both rovalpituzumab tesirine and matching placebo will be supplied as a lyophilized', 'powder in a vial. Each vial of rovalpituzumab tesirine or placebo will be reconstituted', 'with 3.2 mL of sterile water for injection. When reconstituted, vial of rovalpituzumab', 'tesirine will contain 10 mg/mL (30 mg total per vial). The rovalpituzumab tesirine drug', 'product is dosed based on actual body weight. The contents of two or more vials of', 'reconstituted drug product may be required to accomplish the desired dose. The total', 'volume administered treatment arm will be dependent upon the assigned dose. The', 'rovalpituzumab tesirine drug product and placebo solution(s) will be administered via', 'intravenous (IV) infusion. Rovalpituzumab tesirine drug product and placebo solution(s)', 'will be added to 50 mL or 100 mL of 0.9% normal saline with an infusion over', '30 minutes (20 - 45 minute infusion window). The rate should be adjusted based on', 'patient tolerability. Specific dose preparation and documentation details will be provided', 'to the site pharmacy in a separate document. A complete description of the chemistry and', \"formulation may be found in the Investigator's Brochure.14\", '5.5.3', 'Method of Assigning Subjects to Treatment Arms', 'All subjects in the study will be randomized using an IRT system. Before the study is', 'initiated, directions for the IRT will be provided to each site. The site will contact the IRT', 'to obtain a Screening (subject) number once the subject has signed the informed consent', 'and a study-specific procedure has been performed (i.e., central laboratory samples', 'drawn). Once the screening number is assigned, if the subject is not randomized into the', 'study, the reason for screen failure will be documented in the source document and in the', 'eCRF. For others, the site will access the system and a unique randomization number will', 'be provided.', '67']\n\n###\n\n", "completion": "END"}